Faulty List At SAIHST, we have faculties from various backgrounds such as ; basic science, clinical medicine, pharmacology, engineering, business etc. SAIHST is always open for future competent faculties to lead biomedical science.

RYU, GYUHA / Ph.D.

Name : RYU, GYUHA  Ph.D. Department : SAIHST Title : Professor Campus : SMC Campus Office : Annex B3F E-mail : gyuha.ryu@samsung.com, gyuharyu@gmail.com Homepage : Lab. title : Related Department : Medical Device Management and Research Print

■ Careers 1987      BS, Seoul National University (Microbiology) 1993      PhD, Seoul National University (Biomedical Engineering) 1993      Postdoctoral Research Associate, CCCD, University of Utah, Salt Lake City, UT, USA 1995∼1996 Postdoctoral Research Associate, Department of Molecular & Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA 1996 –2002 Senior Research Officer, Medical Device Evaluation & Approval Division, Korea Food & Drug Administration 2002–2008 Director, Medical Device Evaluation & Approval Division, Korea Food & Drug Administration 2008–2012 Director General, Medical Device Evaluation & Approval Department, Korea Food & Drug Administration 2013–2014 Invited Professor, Department of Molecular & Cellular Biology, School of Medicine, Sungkyunkwan University Present    Professor, Department of Medical Device Management & Research, SAIHST, School of Medicine, Sungkyunkwan University Present    Director, A-CRO Team, Research Institute for Future Medicine, Samsung Medical Center ■ Research Summary The mission of our office is to promote the development strategies of R&BD, planning & design, approval, quality management, Clinical trial, Post-market surveillance of medical devices and to create new healthcare service based on digital health & personalized medicine. We are also trying to cultivate global healthcare professionals. Detailed research areas are as follows : (1) Medical products (medical devices, biotechnology, tissue & cell products) and healthcare services related law (2) Approval, quality management, compliance, reimbursement and pricing review of medical products (3) R&BD management of medical products (4) Needs of companies for mergers and acquisitions, new product launches etc. (5) Changes of regulatory requirements in mature and emerging markets (6) Solution to administrative disposition (pre- or post-market control) (7) Solutions to complex legal challenges ■ Keyword Medical device, Biopharmaceuticals, Approval, quality management, Clinical trial, Post-market surveillance, Digital health, Personalized medicine, Healthcare service ■ Selected Publications 1. Prevention effect of orally active heparin conjugate on cancer-associated thrombosis, J Control Release 2014  pii: S0168-3659(14)00330-7.